title: Does DRD2 polymorphism influence the clinical characteristics of prolactinoma?
abstract: OBJECTIVE
  Genetic alterations explaining the clinical variability of prolactinomas still could not be clarified and dopamine D2 receptor (DRD2) polymorphism is a putative candidate for the variable response to dopaminergic treatment. The present study was conducted to investigate the influence of DRD2 TaqI A polymorphism on initial and follow-up characteristics of prolactinoma.
  
  
  METHODS
  Seventy-two patients with prolactinoma and 98 age and gender matched control subjects were recruited to the case-control study. Serum prolactin levels were assessed by enzyme-linked immunosorbent assay and DRD2 polymorphism was determined by polymerase chain reaction and restriction length polymorphism analysis.
  
  
  RESULTS
  Decrease of prolactin levels and the tumor shrinkage after cabergoline treatment were 93.9±5.9% and 58.3±33.1% in microadenomas and 96.1±6.1% and 51.7±29.3 in macroadenomas (P=0.02 and P>0.05, respectively). We observed no significant difference for DRD2 genotypes and the alleles between the patients and healthy group (P>0.05). Prolactin levels before treatment were correlated with tumor diameter before and after treatment and the percentage of prolactin decrease with treatment (P<0.001 r=0.58, P<0.001 r=0.40 and P<0.001 r=0.47, respectively). Tumor diameter before the treatment was also correlated with the tumor diameter after the treatment (P<0.001 r=0.64) and the percentage of prolactin decrease (P=0.01 r=0.30). However, no significant association was found between characteristics of prolactinoma and DRD2 genotypes and alleles (P>0.05).
  
  
  CONCLUSIONS
  This study revealed that DRD2 TaqI A receptor polymorphism was not associated with the development of prolactinoma and its clinical characteristics. Future studies are needed to clarify the clinical implications of genetic alterations in prolactinoma.
authors.affiliation: Bezmialem University, Department of Endocrinology and Metabolism, Vatan Caddesi, 34093 Istanbul, Turkey. Electronic address: muzoilhan@yahoo.com.
authors.forename: Muzaffer
authors.initials: M
authors.lastname: Ilhan
authors.affiliation: The Institute of Experimental Medicine, Department of Molecular Medicine, Millet Caddesi, Capa, Istanbul University, Istanbul, Turkey.
authors.forename: Ozlem Timirci
authors.initials: OT
authors.lastname: Kahraman
authors.affiliation: The Institute of Experimental Medicine, Department of Molecular Medicine, Millet Caddesi, Capa, Istanbul University, Istanbul, Turkey.
authors.forename: Saime
authors.initials: S
authors.lastname: Turan
authors.affiliation: Bezmialem University, Internal Medicine Department, Vatan Caddesi, 34093 Istanbul, Turkey.
authors.forename: Seda
authors.initials: S
authors.lastname: Turgut
authors.affiliation: Bezmialem University, Department of Endocrinology and Metabolism, Vatan Caddesi, 34093 Istanbul, Turkey.
authors.forename: Ozcan
authors.initials: O
authors.lastname: Karaman
authors.affiliation: The Institute of Experimental Medicine, Department of Molecular Medicine, Millet Caddesi, Capa, Istanbul University, Istanbul, Turkey.
authors.forename: Umit
authors.initials: U
authors.lastname: Zeybek
authors.affiliation: Bezmialem University, Department of Endocrinology and Metabolism, Vatan Caddesi, 34093 Istanbul, Turkey.
authors.forename: Samir
authors.initials: S
authors.lastname: Shukurov
authors.affiliation: The Institute of Experimental Medicine, Department of Molecular Medicine, Millet Caddesi, Capa, Istanbul University, Istanbul, Turkey.
authors.forename: Ilhan
authors.initials: I
authors.lastname: Yaylim
authors.affiliation: Bezmialem University, Department of Endocrinology and Metabolism, Vatan Caddesi, 34093 Istanbul, Turkey.
authors.forename: Ertugrul
authors.initials: E
authors.lastname: Tasan
mesh_terms: D000328:Adult; D000483:Alleles; D000970:Antineoplastic Agents; D000077465:Cabergoline; D016022:Case-Control Studies; D018491:Dopamine Agonists; D004873:Ergolines / Q000627:therapeutic use; D005260:Female; D005838:Genotype; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic / Q000235:genetics*; D012150:Polymorphism, Restriction Fragment Length; D011388:Prolactin / Q000097:blood; D015175:Prolactinoma / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D017448:Receptors, Dopamine D2 / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D018491:Dopamine Agonists; D004873:Ergolines; D017448:Receptors, Dopamine D2; D011388:Prolactin; D000077465:Cabergoline
keywords: DRD2; Polymorphism; Polymorphisme; Prolactinoma; Prolactinome